支气管肺动脉成形术治疗中央型肺癌的临床分析

Objective The aim of this study is to review the surgical experience of bronchoplasty and pulmo-nary arterioplasty in treatment of central-type lung cancer. Methods From 2003 to 2005,36 cases of patients with central-type lung cancer underwent bronchoplasty and pulmonary arterioplasty. There were 28 males and 8 females with a mean age of 62 years. Accordlng to pTNM classification. 5 cases were in stage ⅡI B,and 27 in stage Ⅲ A and 4 in stage Ⅲ B. Histologically,there were 24 cases of squamous cell carcinoma,6 cases of adenocarcinoma,1 case of small cell lung cancer and 5 cases of adenesquamous carcinoma. Results No patients died in the perioperative peri-od. The overall 1-,3-, and 5-year survival rate were 74% (26/35) ,48% (11/23) and 33% (3/9) ,respectively.Conclusion The results suggest that bronchoplasty and pulmonary arterioplasty can decrease the proportions of total pneumonectomy and exploratory thoracetomy and expand the indication of operation. Bronchoplasty and pulmonary ar-terioplasty can be achieved with satisfactory outcome for central-type lung cancer,especially for those patients with ad-vanced lesions or poor pulmonary function.     

支气管肺动脉成形术治疗中央型肺癌的临床分析

Objective The aim of this study is to review the surgical experience of bronchoplasty and pulmo-nary arterioplasty in treatment of central-type lung cancer. Methods From 2003 to 2005,36 cases of patients with central-type lung cancer underwent bronchoplasty and pulmonary arterioplasty. There were 28 males and 8 females with a mean age of 62 years. Accordlng to pTNM classification. 5 cases were in stage ⅡI B,and 27 in stage Ⅲ A and 4 in stage Ⅲ B. Histologically,there were 24 cases of squamous cell carcinoma,6 cases of adenocarcinoma,1 case of small cell lung cancer and 5 cases of adenesquamous carcinoma. Results No patients died in the perioperative peri-od. The overall 1-,3-, and 5-year survival rate were 74% (26/35) ,48% (11/23) and 33% (3/9) ,respectively.Conclusion The results suggest that bronchoplasty and pulmonary arterioplasty can decrease the proportions of total pneumonectomy and exploratory thoracetomy and expand the indication of operation. Bronchoplasty and pulmonary ar-terioplasty can be achieved with satisfactory outcome for central-type lung cancer,especially for those patients with ad-vanced lesions or poor pulmonary function.     

颅脑损伤致上消化道出血46例分析

我院自1987～1991年共收治颅脑损伤病人242例,其中并发上消化道出血46例,占19％。现报告如下。 1 临床资料 本组242例病人,均于伤后24小时入院,无严重合并伤,男184例,女58例;最小年龄7个月,最大年龄82岁。脑干损伤26例,合并上消化道出血9例(34.61％),死亡4例。脑挫裂伤114例,出血15例(13.15％),死亡7例,急性硬膜下血肿48例,出血16例(33.33％),死亡5例,硬膜外血肿54例,出血6例(11.11％),死亡1例。     

支气管肺动脉成形术治疗中央型肺癌的临床分析

Objective The aim of this study is to review the surgical experience of bronchoplasty and pulmo-nary arterioplasty in treatment of central-type lung cancer. Methods From 2003 to 2005,36 cases of patients with central-type lung cancer underwent bronchoplasty and pulmonary arterioplasty. There were 28 males and 8 females with a mean age of 62 years. Accordlng to pTNM classification. 5 cases were in stage ⅡI B,and 27 in stage Ⅲ A and 4 in stage Ⅲ B. Histologically,there were 24 cases of squamous cell carcinoma,6 cases of adenocarcinoma,1 case of small cell lung cancer and 5 cases of adenesquamous carcinoma. Results No patients died in the perioperative peri-od. The overall 1-,3-, and 5-year survival rate were 74% (26/35) ,48% (11/23) and 33% (3/9) ,respectively.Conclusion The results suggest that bronchoplasty and pulmonary arterioplasty can decrease the proportions of total pneumonectomy and exploratory thoracetomy and expand the indication of operation. Bronchoplasty and pulmonary ar-terioplasty can be achieved with satisfactory outcome for central-type lung cancer,especially for those patients with ad-vanced lesions or poor pulmonary function.     

支气管肺动脉成形术治疗中央型肺癌的临床分析

目的探讨支气管肺动脉成形术治疗肺癌的效果。方法自2003年至2005年对36例肺癌患者施行支气管肺动脉同时成形术。术后病理诊断结果：鳞癌24例,腺癌6例,腺鳞癌5例,小细胞未分化癌1例。pTNM分期：ⅡB期5例（T2N1M0 4例,T3N0M0 1例）,ⅢA期27例（T3N1M0 11例,T2N2M0 9例,T3N2M0 7例）,ⅢB期4例（T4N0M0 1例,T4N1M0 1例,T4N2M0 2例）。结果该组手术近期死亡0例。术后1、3、5年生存率分别为74％（26／35）、48％（11／23）、33％（3／9）。结论采用支气管肺动脉同时成形术治疗中央型肺癌减少了全肺切除和单纯剖胸探查的率扩大了手术适应证,为肺癌患者提供了更有效、安全、合理的治疗机会。     

经胸骨上窝横切口行胸腺切除治疗胸腺瘤合并重症肌无力

目的 探讨经胸骨上窝横切口行胸腺切除治疗胸腺瘤合并重症肌无力(MG)的临床疗效.方法 回顾分析经胸骨上窝横切口手术治疗的32例胸腺瘤合并MG的临床资料,分析其手术径路及围手术期处理等.结果 术后9例患者发生MG危象,死亡率为6%,无1例患者因出血或无法完整切除胸腺而中转开胸.结论 经胸骨上窝横切口行胸腺切除治疗重症肌无力,有创伤小、术后疼痛轻、并发症少等特点,是一种安全有效的手术方式.     

胆总管巨大结石1例

患者女,74岁。因阵发性右上腹剧痛4年,腹痛发作伴发冷、发热6天入院。有胆总管结石手术史。体检:体温37.8℃,巩膜轻度黄染,右上腹压     

支气管肺动脉成形术治疗中央型肺癌的临床分析

Objective The aim of this study is to review the surgical experience of bronchoplasty and pulmo-nary arterioplasty in treatment of central-type lung cancer. Methods From 2003 to 2005,36 cases of patients with central-type lung cancer underwent bronchoplasty and pulmonary arterioplasty. There were 28 males and 8 females with a mean age of 62 years. Accordlng to pTNM classification. 5 cases were in stage ⅡI B,and 27 in stage Ⅲ A and 4 in stage Ⅲ B. Histologically,there were 24 cases of squamous cell carcinoma,6 cases of adenocarcinoma,1 case of small cell lung cancer and 5 cases of adenesquamous carcinoma. Results No patients died in the perioperative peri-od. The overall 1-,3-, and 5-year survival rate were 74% (26/35) ,48% (11/23) and 33% (3/9) ,respectively.Conclusion The results suggest that bronchoplasty and pulmonary arterioplasty can decrease the proportions of total pneumonectomy and exploratory thoracetomy and expand the indication of operation. Bronchoplasty and pulmonary ar-terioplasty can be achieved with satisfactory outcome for central-type lung cancer,especially for those patients with ad-vanced lesions or poor pulmonary function.     

巨大胸膜脂肪瘤误诊为肺良性肿瘤1例

患者男,3岁。发现左侧胸壁包块2年,2年来无不适,包块渐长大。查体发现左胸壁5、6肋处一大小4cm×3cm包块,质韧,无压痛,边界清,活动度可,听诊左下胸部呼吸音低。 胸部X线检查:左肺野中、下部示一圆形密度增高影,7cm×8cm大小,边缘清,密度均匀。纵隔、心影向右稍示移位,左第5、6前肋均示受压,第5前肋下缘,第6前肋上缘可见弧形压迫,肋间隙增宽,侧位位于后基底段,阴影部分与脊柱相重叠。各项实验室检查结果均正常。初步诊断为“肺良性肿瘤”,拟行剖胸探查。     

多西他赛治疗晚期非小细胞肺癌68例临床观察

目的评价多西他赛治疗晚期非小细胞肺癌（NSCLC）的临床疗效和安全性。方法按照数字表法随机将晚期肺癌分为治疗组和对照组,每组34例;治疗组采用多西他赛35mg/m2溶于生理盐水静脉滴注;对照组采用长春瑞滨35mg/m2溶于生理盐水静脉滴注,评价两组病例的治疗效果和不良反应。结果两组药物近期治疗效果和不良反应差异无统计学意义（P〉0．05）;多西他赛中位无疾病进展生存期较长春瑞滨延长,提高了有效率,并且在改善肿瘤相关症状方面具有优势。结论多西他赛和长春瑞滨治疗晚期非小细胞肺癌近期疗效相近,但多西他赛能改善客观有效率,延长患者疾病进展时间,是一种安全、有效的治疗药物。